前の章|次の章

「痹」論に基づく特発性肺線維症治療の研究進展

  • role： First author第一作者
  • Affiliation：

    Changchun University of Chinese Medicine， Changchun 130117，China

  • Email：17839512659@163.com
  • Introduction：陈思玉，在读硕士，住院医师，从事中西医结合临床内科疾病方向的研究，E-mail：17839512659@163.com
CHEN Siyu1,  
  • Affiliation：

    Changchun University of Chinese Medicine， Changchun 130117，China

CAO Zhenghua1,  
  • Affiliation：

    Changchun University of Chinese Medicine， Changchun 130117，China

XU Rong1,  
  • Affiliation：

    Changchun University of Chinese Medicine， Changchun 130117，China

LI Qingrong1,  
  • Affiliation：

    Changchun University of Chinese Medicine， Changchun 130117，China

BI Yanze1,  
  • Affiliation：

    Changchun University of Chinese Medicine， Changchun 130117，China

SHANG Boyi1,  
  • role： Corresponding author通信作者
  • Affiliation：

    The Affiliated Hospital of Changchun University of Chinese Medicine， Changchun 130000，China

  • Email：734168300@qq.com
  • Introduction：胡少丹，硕士，副主任医师，从事中医药防治呼吸系统疾病的研究，E-mail：734168300@qq.com
HU Shaodan2*

サマリー

特発性肺線維症（IPF）は慢性線維化を伴う致死的な間質性肺疾患であり、予後不良です。現在のIPF治療は主に臓器移植と化学薬物投与に依存していますが、効果は不十分で副作用も多く、現行の臨床ニーズを満たしていません。したがって、より安全で効果的な新しい治療薬の探索が急務です。中医学によるIPF治療は、その独自の利点により近年注目を集めており、益々多くの研究が中医学のIPF予防および治療効果が顕著であり、広範な応用展望があることを示しています。現代医学の研究によれば、炎症（マクロファージの極性化）、酸化ストレス、上皮-間質転換（EMT）、オートファジー抑制など関連するシグナル経路の観点からIPFの発病機序を論じることができますが、各シグナル経路と中医学理論との体系的な関連性を示す研究はまだありません。中医学理論では「肺絡痹阻」がIPFの基本病機と考えられており、肺絡を通じて補うことを原則に正気を扶正し邪気を祛り気を益し活血し解毒し絡を通じてIPFを治療します。この治療は臨床症状を効果的に緩和し、肺機能や血中酸素分圧を改善し、患者の生活の質を向上させ、副作用を軽減します。実験研究では、肺絡通補法に基づく介入が炎症（マクロファージの極性化）、酸化ストレス、EMT、オートファジー抑制などの主要シグナル経路に顕著な効果があることが示されました。本論文は「痹」の観点からIPFの発病機序、中医学IPF治療研究の進展、「単体-中薬-複方」の観点からIPF治療を総説し、痹論によるIPF治療の科学的内涵を明らかにし、中医学IPF治療法の充実に新たな理論的根拠を提供します。

キーワード

特発性肺線維症;肺痹;肺絡通補;絡病理論;生物学的機序

References

  1. 1.
    PEREZ-FAVILA A，GARZA-VELOZ I，HERNANDEZ-MARQUEZ L D S，et al.Antifibrotic drugs against idiopathic pulmonary fibrosis and pulmonary fibrosis induced by COVID-19：Therapeutic approaches and potential diagnostic biomarkers［J］.Int J Mol Sci，2024，25（3）：1562
  2. 2.
    RAGHU G，REMY-JARDIN M，RICHELDI L，et al.Idiopathic pulmonary fibrosis（an update）and progressive pulmonary fibrosis in adults：An official ATS/ERS/JRS/ALAT clinical practice guideline［J］.Am J Respir Crit Care Med，2022，205（9）：e18-e47.
  3. 3.
    ANTONIOU K M，TSITOURA E，VASARMIDI E，et al.Precision medicine in idiopathic pulmonary fibrosis therapy：From translational research to patient-centered care［J］.Curr Opin Pharmacol，2021，doi：.
  4. 4.
    RAGHU G，ROCHWERG B，ZHANG Y，et al.An official ATS/ERS/JRS/ALAT clinical practice guideline：Treatment of idiopathic pulmonary fibrosis.An update of the 2011 clinical practice guideline［J］.Am J Respir Crit Care Med，2015，192（2）：e3-e19.
  5. 5.
    ZOU E G，HUANG T Y，WANG M L，et al.Pathogenesis of idiopathic pulmonary fibrosis and modulating effect of Chinese medicine：A review［J］.Chin J Exp Tradit Med Form，2019，30（10）：280-289.
  6. 6.
    WANG Y R，ZHANG W J，ZHANG W.Research progress in the treatment of idiopathic pulmonary fibrosis with traditional Chinese medicine［J］.Intern Med J Pract Tradit Chin Med Sci，2024，38（5）：31-35.
  7. 7.
    CUI H S，QIU D M，WU W P.Study on treatment of pulmonary interstitial fibrosis based on syndrome differentiation of collateral diseases［J］.J Tradit Chin Med，2003，（12）：946-947.
  8. 8.
    JIANG L D，ZHANG X M，XIAO P X.Discussion on etiopathogenisis and pathogenesis of idiopathic pulmonary fibrosis［J］.China J Tradit Chin Med Pharm，2008，23（11）：984-986.
  9. 9.
    WU Y G，ZHANG T S.Approach to collateral theory for guiding TCM diagnosis and treatment of pulmonary fibrosis［J］.Chin Arch Tradit Chin Med，2005，23（1）：14-5，19-123.
  10. 10.
    YUAN C B，WANG T，ZHANG L X，et al.Experience of professor WANG Tan in the treatment of interstitial lung disease based on syndrome differentiation［J］.Chin Med Mod Dist Educ China，2020，18（17）：80-81.
  11. 11.
    GAO Y R，LIU Q，ZHANG W.Clinical study of Fuzheng Tongluo decoction in the treatment of pulmonary and kidney qi deficiency syndrome of idiopathic pulmonary fibrosis［J］.J Liaoning Univ Tradit Chin Med，2020，22（7）：172-176.
  12. 12.
    LI L，SHEN Y H，YUAN X H，et al.Clinical efficacy study of Fuzheng Huayu formula combined with pirfenidone in treating idiopathic pulmonary fibrosis［J］.Acta Univ Tradit Chin Med Sin Pharmcol Shanghai，2024，38（1）：52-60.
  13. 13.
    YAN J J，ZHOU L，GUAN X F.Effect of Qingfei Huaxian decoction on pulmonary function and pulmonary fibrosis index in patients with idiopathic pulmonary fibrosis［J］.Chin Foreign Med Res，2020，18（10）：13-15.
  14. 14.
    WEI G S，QIANG N X.Idiopathic pulmonary fibrosis treated by Tongfei Huoxue decoction［J］.Shaanxi J Tradit Chin Med，2007，28（4）：389-390.
  15. 15.
    CHEN H L.Therapeutic effect of supplementing lung Tongluo and promoting blood circulation to remove blood stasis in the treatment of pulmonary fibrosis［J］.Neimonggu J Tradt Chin Med，2016，35（15）：54.
  16. 16.
    SONG S Y，DING L，ZHAO M R，et al.Research progress of Chinese medicine pathogenesis and prevention strategies for idiopathic pulmonary fibrosis［J］.China J Tradit Chin Med Pharm，2024，39（11）：6020-6025.
  17. 17.
    PANG L J.Study on the intervention of TCM compound in IPF TGF-β1/Smads signaling pathway and the mechanism of Th1/Th2 imbalance based on lung collateral theory［D］.Shenyang：Liaoning University of Traditional Chinese Medicine，2015.
  18. 18.
    LI Y J，PANG L J，LV X D，et al.Exploration of the lncRNA-miRNA-mRNA regulatory network in Chinese medicine for the prevention and treatment of idiopathic pulmonary fibrosis based on the theory of collateral disease［J］.J Liaoning Univ Tradit Chin Med，2024，26（4）：148-152.
  19. 19.
    SARI E，HE C，MARGAROLI C.Plasticity towards rigidity：A macrophage conundrum in pulmonary fibrosis［J］.Int J Mol Sci，2022，23（19）：11443.
  20. 20.
    MILLS C D.Anatomy of a discovery：M1 and m2 macrophages［J］.Front Immunol，2015，6：212.
  21. 21.
    SHI X Y.The role and mechanism of M2 macrophages in lipopolysaccharide-induced pulmonary fibrosis［D］.Nanchang：Nanchang University，2021.
  22. 22.
    GUO Z J，ZHAI H Q，WANG N N，et al.Study of macrophage polarization on pulmonary fibrosis and signaling pathway［J］.China J Chin Mater Med，2018，43（22）：4370-4379.
  23. 23.
    TONG B，FU L，HU B，et al.Tauroursodeoxycholic acid alleviates pulmonary endoplasmic reticulum stress and epithelial-mesenchymal transition in bleomycin-induced lung fibrosis［J］.BMC Pulm Med，2021，21（1）：149.
  24. 24.
    VAN DER VLIET A，JANSSEN-HEININGER Y M W，ANATHY V.Oxidative stress in chronic lung disease：From mitochondrial dysfunction to dysregulated redox signaling［J］.Mol Aspects Med，2018，63：59.
  25. 25.
    CHEN K，ZHANG L X，TIAN Y G，et al.Mechanism of oxidative stress in chronic obstructive pulmonary disease and progress of TCM treatment［J］.Chin J Gerontol，2022，42（19）：4881-4885.
  26. 26.
    BOLOURANI S，BRENNER M，WANG P.The interplay of DAMPs，TLR4 and proinflammatory cytokines in pulmonary fibrosis［J］.J Mol Med，2021，99（10）：1373-1384.
  27. 27.
    BOROK Z，BUHL R，GRIMES G J，et al.Effect of glutathione aerosol on oxidant-antioxidant imbalance in idiopathic pulmonary fibrosis［J］.Lancet，1991，338（8761）：215-216.
  28. 28.
    WANG L，LI S，YAO Y，et al.The role of natural products in the prevention and treatment of pulmonary fibrosis：A review［J］.Food Funct，2021，12（3）：990-1007.
  29. 29.
    BAI Y，LI J，ZHAO P，et al.A Chinese herbal formula ameliorates pulmonary fibrosis by inhibiting oxidative stress via upregulating Nrf2［J］.Front Pharmacol，2018，9：628.
  30. 30.
    BARTIS D，MISE N，MAHIDA R Y，et al.Epithelial-mesenchymal transition in lung development and disease：Does it exist and is it important？［J］.Thorax，2014，69（8）：760-765.
  31. 31.
    JOLLY M K，WARD C，EAPEN M S，et al.Epithelial-mesenchymal transition，a spectrum of states：Role in lung development，homeostasis，and disease［J］.Dev Dyn，2018，247（3）：346-358.
  32. 32.
    SALTON F，VOLPE M C，CONFALONIERI M.Epithelial-mesenchymal transition in the pathogenesis of idiopathic pulmonary fibrosis［J］.Medicina，2019，55（4）：83.
  33. 33.
    YUE Y L，ZHANG M Y，LIU J Y，et al.The role of autophagy in idiopathic pulmonary fibrosis：From mechanisms to therapies［J］.Ther Adv Respir Dis，2022，16：17534666221140972.
  34. 34.
    MARGARITOPOULOS G A，TSITOURA E，TZANAKIS N，et al.Self-eating：Friend or foe？ The emerging role of autophagy in idiopathic pulmonary fibrosis［J］.Biomed Res Int，2013，2013：420497.
  35. 35.
    HILL C，LI J，LIU D，et al.Autophagy inhibition-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis［J］.Cell Death Dis，2019，10（8）：591.
  36. 36.
    ARAYA J，KOJIMA J，TAKASAKA N，et al.Insufficient autophagy in idiopathic pulmonary fibrosis［J］.Am J Physiol Lung Cell Mol Physiol，2013，304（1）：L56-L69.
  37. 37.
    NAKAHIRA K，PABON PORRAS M A，CHOI A M.Autophagy in pulmonary diseases［J］.Am J Respir Crit Care Med，2016，194（10）：1196-1207.
  38. 38.
    FU J，LU L，WANG H，et al.Hirsutella sinensis mycelium regulates autophagy of alveolar macrophages via TLR4/NF-κB signaling pathway［J］.Int J Med Sci，2021，18（8）：1810-1823.
  39. 39.
    JESSOP F，HAMILTON R F，RHODERICK J F，et al.Autophagy deficiency in macrophages enhances NLRP3 inflammasome activity and chronic lung disease following silica exposure［J］.Toxicol Appl Pharmacol，2016，309：101.
  40. 40.
    ZHAO P，CAI Z，TIAN Y，et al.Effective-compound combination inhibits the M2-like polarization of macrophages and attenuates the development of pulmonary fibrosis by increasing autophagy through mTOR signaling［J］.Int Immunopharmacol，2021，101（Pt B）：108360.
  41. 41.
    KE S W，LI S F，ZHANG Y B，et al.Rethink of treating interstitial pulmonary fibrosiswith warming therapeutic method throughout the entire treatment period［J］.China J Tradit Chin Med Pharm，2019，34（9）：4078-4081.
  42. 42.
    ZHANG Y，LI F Y，YAN Y Y，et al.Application of TCM "Tong" method in treating non-disease［J］.Global Tradit Chin Med，2016，9（6）：707-708.
  43. 43.
    ZHAO H X，WANG W L，ZHAO K W.Understanding the connotations of Zheng-Qi in Huangdi Neijing［J］.China J Basic Med Tradit Chin Med，2009，15（8）：579.
  44. 44.
    MENG L H，XUE X M，ZHANG X M，et al.Treatment on idiopathic pulmonary fibrosis from the perspective of state theory［J］.China J Tradit Chin Med Pharm，2023，38（4）：1576-1579.
  45. 45.
    ZHAO Y P，WENG W L，LI Q Y，et al.Academic thought on "eliminating pathogens for balancing and replenishing" and its clinical application［J］.World J Integr Tradit West Med，2014，9（10）：1116-1118.
  46. 46.
    WEI Y，YE H Y，ZHAO G J，et al.Mechanism of Fuzheng Huaxian formula in the treatment of idiopathic pulmonary fibrosis based on network pharmacology and molecular docking［J］.J Navy Med，2024，45（2）：180-185.
  47. 47.
    ZHAO G J，HU H B，HAN P，et al.Clinical study of idiopathic pulmonary fibrosis treated with Fuzheng Huaxian formula［J］.Shandong J Tradit Chin Med，2018，37（1）：22-25.
  48. 48.
    JIANG W，WANG J，WANG F C，et al.Effects of aqueous decoction of Fuzheng Huaxian formula on bleomycin-induced pulmonary fibrosis and CFTR expression in mouse lung tissue［J］.Chin Tradit Pat Med，2022，44（11）：3468-3475.
  49. 49.
    FENG J W，HUANG K，JING F，et al.Effect of FuzhengHuayu formula regulating TGF-β/Smad signaling pathway on bleomycin-induced pulmonary fibrosis in mice［J］.Chin Tradit Pat Med，2024，46（6）：2042-2047.
  50. 50.
    JING F，HU X D，PENG Y，et al.Exploring the effects of Fuzheng Huayu formula on PI3K-Akt signaling pathway in mice with pulmonary fibrosis based on network pharmacology［J］.Chin J Inf Tradit Chin Med，2022，29（2）：28-33.
  51. 51.
    CHEN F，DUAN N F，ZHANG X，et al.Effect of Fuzheng Tongluo granules on macrophage pyroptosis in rat model with pulmonary fibrosis based on NLRP3/Caspase-1/GSDMD pathway［J］.China J Chin Mater Med，2024，49（23）：6399-6406.
  52. 52.
    ZHANG X，ZHANG W，CAI G.Effects of Fuzheng Tongluo formula on autophagy in treating pulmonary fibrosis［J］.China J Tradit Chin Med Pharm，2020，35（11）：5455-5459.
  53. 53.
    LIAN Y G，ZHENG F J，ZHANG N，et al.Effect of Fuzheng Tixie Souluo formula on partial pressure of blood oxygen in pulmonary fibrosis rats［J］.China J Chin Med，2023，38（9）：1961-1965.
  54. 54.
    ZHANG N，ZHENG F J，WU H Y，et al.Influence of Fuzheng Tixie Souluo formula on angiogenesis in rats with pul-monary fibrosis［J］.J Beijing Univ Tradit Chin Med，2018，41（5）：376-382.
  55. 55.
    WANG Y J，WANG X L，LI X Z，et al.Study on the treatment of idiopathic pulmonary fibrosis with traditional Chinese medicine［J］.China J Basic Med Tradit Chin Med，2021，27（6）：1033-1035.
  56. 56.
    WANG Y M，DONG H R，MENG Y，et al.Meta-analysis on efficacy of treatment based on benefiting Qi for activating blood circulation method in idiopathic pulmonary fibrosis of Qi deficiency and blood stasis type［J］.World Sci Technol Mod Tradit Chin Med，2020，22（9）：3110-3115.
  57. 57.
    SUN Z T，FENG J H，LI X J，et al.Effect of supplementing Qi and Huoxue dispersing knot on quality of life of patients with idiopathic pulmonary fibrosis［J］.J Tradit Chin Med，2007，48（10）：907-908.
  58. 58.
    TAO L X，PENG S J，ZHANG J W，et al.Effect of supplementing Qi Huoxue decoction combined with glucocorticoid on blood gas indexes in patients with pulmonary fibrosis［J］.Chin J Gerontol，2022，42（10）：2388-2391.
  59. 59.
    PENG W P，WANG D，WU Q，et al.Potential mechanism of Bufei Huoxue capsule in treating pulmonary fibrosis based on network pharmacology［J］.Nat Prod Res Dev，2024，36（6）：1056-1063，1055.
  60. 60.
    ZHANG W Z，XU Y，HAN D，et al.Mechanism study of Dangshen Pingfei Huoxue decoction in treatment of pulmonary fibrosis based on network pharmacology and molecular docking［J］.Chin Pharmacol Bull，2023，39（6）：1165-1173.
  61. 61.
    ZHANG C F，WANG Z X，YANG K，et al.The analysis of mechanism of Buyang Huanwu Tang in treating pulmonary fibrosis disease based on Fang syndrome factor correspondence［J］.Lishizhen Med Mater Med Res，2018，29（6）：1406-1408.
  62. 62.
    ZHOU W，LUO Y L，ZHOU S Q，et al.To explore the effect of Yiqi Yangyin Huoxue formula on pulmonary fibrosis based on network pharmacology and animal experiments［J］.Chin Tradit Pat Med，2023，45（3）：973-978.
  63. 63.
    LIU Y M，LI S Y，PANG L J，et al.Effect of Yiqi Yangyin Huoxue Tongluo formula on platelet activation and lung tissue CD40-CD40L system in idiopathic pulmonary fibrosis model rats［J］.J Tradit Chin Med，2023，64（5）：504-511.
  64. 64.
    HE Q W，HUANG W H，SHEN X，et al.Study on the improvement effect of Qidong Huoxue decoction on bleomycin-induced pulmonary fibrosis by regulating PI3K/Akt/mTOR signaling pathway［J］.J Chin Med Mater，2024，47（5）：1240-1246.
  65. 65.
    LIU H M，JIA X H，TIAN L，et al.Discussion on myofibroblast activation mechanism in idiopathic pulmonary fibrosis from the theory of 'toxic pulmonary collateral injury'［J］.China J Tradit Chin Med Pharm，2022，37（2）：646-649.
  66. 66.
    CAO Y Y，XU X，LI W.Exploration of the mechanism of Qingfei Jiedu decoction in the treatment of pulmonary fibrosis based on network pharmacology and molecular docking technology［J］.Chin Pharm Aff，2024，38（6）：653-664.
  67. 67.
    ZHAO Q B，CHI T H，PANG L J，et al.A retrospective observation on effect of reduning injection on acute idiopathic pulmonary fibrosis［J］.Chin Arch Tradit Chin Med，2017，35（3）：680-682.
  68. 68.
    WANG Z C，HE Y Z，ZHAO D L，et al.Effect of Danshen Tongluo Jiedu decoction on tumor necrosis factor-like weak inducer of apoptosis/fibroblast growth factor-inducible 14 pathway in mice with pulmonary fibrosis induced by bleomycin［J］.J Xinxiang Med Coll，2021，38（12）：1101-1112.
  69. 69.
    YAN S H.Efficacy evaluation and mechanism of Yinhuang granules in improving pulmonary fibrosis and liver fibrosis in mice［D］.Shanghai：Shanghai University of Traditional Chinese Medicine，2021.
  70. 70.
    LIU Y T，LYU X D，PANG L J，et al.Modern medicine basis of dredging and supplementing collaterals method reversing the pathogenesis of idiopathic pulmonary fibrosis with lung deficiency and collateral stasis syndrome［J］.J Tradit Chin Med，2017，58（16）：1381-1384.
  71. 71.
    QU J L，GONG J N.Research progress of mechanism of traditional Chinese medicine in prevention and treatment of pulmonary fibrosis［J］.China J Basic Med Tradit Chin Med，2015，21（6）：772-775.
  72. 72.
    TANG H B，WANG Q，TANG H Y，et al.Therapeutic effect and mechanism of curcumin and PPAR-γ/PDGFB-β on pulmonary fibrosis［J］.Chin J Gerontol，2024，44（17）：4193-4197.
  73. 73.
    LIANG Y Y，LIU S H，LUO M H，et al.Effects and mechanism of oxymatrine on bleomycin-induced pulmonary fibrosis in mice［J］.China J Tradit Chin Med Pharm，2024，39（2）：755-760.
  74. 74.
    QIN S B，TAN P，HAO L，et al.Investigating mechanism of fritillariae cirrhosae bulbus against pulmonary fibrosis based on spatial metabolomics［J］.Chin J Exp Tradit Med Form，2024，30（13）：150-159.
  75. 75.
    GUO Z，LI S，ZHANG N，et al.Schisandra inhibit bleomycin-induced idiopathic pulmonary fibrosis in rats via suppressing M2 macrophage polarization［J］.Biomed Res Int，2020，doi：.
  76. 76.
    WANG S，LI Y，LI X M，et al.Effect of Gualou Xiebai decoction on idiopathic pulmonary fibrosis based on TGF-β signaling pathway［J］.Chin Arch Tradit Chin Med，2024，42（5）：219-224，299-300.
  77. 77.
    HE C，CHEN W，ZHANG N Z，et al.Shenqi Chongcao formula ameliorates inflammatory response in rats with pulmonary fibrosis by activating the ASS1/src/STAT3 signaling pathway［J］.J South Med Univ，2024，44（4）：644-651.
  78. 78.
    YANG H，ZHOU S X，LI H M，et al.Exploration on the effects of Shengxian Huaxian formula on pulmonary fibrosis with regulating the polarization of M2 type macrophages based on STAT6/PPAR-γ pathway［J］.Chin J Inf Tradit Chin Med，2025，32（1）：113-119.
  79. 79.
    CHEN Y Q，CHEN Y L，GUO C H，et al.Effect of anwulignan on pulmonary fibrosis in mice and its mechanism［J］.Med J Chin PLA，2022，47（3）：227-236.
  80. 80.
    AN L P，DU Q Y，YANG H，et al.Research progress of mechanism on invigorating Qi and activating blood circulation in the treatment of idiopathic pulmonary fibrosis［J］.World Sci Technol Mod Tradit Chin Med，2023，25（6）：2122-2131.
  81. 81.
    ZHANG B F，ZHOU S H，WANG Z.Trillium saponins ameliorates pulmonary fibrosis in rats by inhibiting TGF-β/Smad3 and Wnt/β-catenin signaling pathways［J］.J Shandong Univ：Health Sci，2022，60（8）：23-29.
  82. 82.
    FANG L，WANG W，CHEN J，et al.Osthole attenuates bleomycin-induced pulmonary fibrosis by modula-ting NADPH oxidase 4-derived oxidative stress in mice［J］.Oxid Med Cell Longev，2021，2021：3309944.
  83. 83.
    WANG Y T，WANG C G，JIA S N，et al.Mechanism of Zedoary Turmeric Oil on attenuating bleomycin-induced pulmonary fibrosis in mice through inhibition of ferroptosis［J］.Chin Tradit Herb Drugs，2023，54（16）：5274-5282.
  84. 84.
    LI J，ZHANG J，CHEN X S.Inhibitory effect of extracts of parsnips with Keap1-Nrf2/ARE axis on pulmonary fibrosis and angiogenesis in young rats with interstitial pneumonia［J］.J Chin Med Mater，2022，45（4）：968-973.
  85. 85.
    YIN X H，BAI Y P，SHAO D，et al.Improvement on pulmonary fibrosis in rats of effective-compound compatibility of Jinshui Huanxian formulaⅡby inhibiting oxidative stress［J］.China J Tradit Chin Med Pharm，2023，38（3）：1213-1217.
  86. 86.
    WEI Y，WANG J，HAN D，et al.Protective effect and mechanism of Maiwei Yangfei decoction on pulmonary fibrosis mice based on Nrf2 regulation of oxidative stress［J］.China J Chin Mater Med，2023，48（24）：6682-6692.
  87. 87.
    ZHAO M Y，LIU Y，JIANG M B，et al.Experimental study on improvement of idiopathic pulmonary fibrosis in rats by activating Nrf2-Keap1 signaling pathway［J］.Pharmacol Clin Chin Mater Med，2022，38（3）：48-52.
  88. 88.
    LIU L J，QIAN H，MENG Q X，et al.Sinomenine inhibits oxidative stress and pulmonary fibrosis by acti-vating the Keap1/Nrf2 signaling pathway［J］.Chin J Clin Pharmacol Ther，2023，28（9）：979-987.
  89. 89.
    LI S S，HUANG J，LI L X，et al.Metabonomic Analysis of Wenfei Huaxian granules against idiopathic pulmonary fibrosis in mice［J］.Chin J Exp Tradit Med Form，2023，29（9）：166-178.
  90. 90.
    DING L，YANG Y，WANG Z，et al.Qimai Feiluoping decoction inhibits mitochondrial complex Ⅰ-mediated oxidative stress to ameliorate bleomycin-induced pulmonary fibrosis［J］.Phytomedicine，2023，112：154707.
  91. 91.
    CAI F L，WANG M F，CHENG X Q，et al.Effect and mechanism of isoliquiritin on pulmonary fibrosis model in vitro［J］.Her Med，2022，41（2）：167-174.
  92. 92.
    HE J，PENG H，WANG M，et al.Isoliquiritigenin inhibits TGF-β1-induced fibrogenesis through activating a-utophagy via PI3K/Akt/mTOR pathway in MRC-5 cells［J］.Acta Biochim Biophys Sin（Shanghai），2020，52（8）：810-820.
  93. 93.
    WANG X Y，CHENG M H，SHENG G L，et al.Cordycepin targets HDAC7 to mediate epithelial-mesenchymal transition to ameliorate pulmonary fibrosis［J］.Acta Pharm Sin，2024，59（6）：1627-1638.
  94. 94.
    YU L，BIAN X，ZHANG C，et al.Ginkgolic acid improves bleomycin-induced pulmonary fibrosis by inhibiting SMAD4 SUMOylation［J］.Oxid Med Cell Longev，2022，2022：8002566.
  95. 95.
    XIAO X，LI L.Astragalus injection attenuates pulmonary fibrosis by inhibiting pERK1/2 signal pathway in process of EMT［J］.Chin J Immunol，2022，38（19）：2342-2345.
  96. 96.
    YAN Y N，LIANG Y L，WANG J P，et al.Improvement of lung function in rats with idiopathic pulmonary fibrosis by Shengxian decoction via regulating cell senescence mediated by Wnt3a/β-catenin signaling pathway［J］.Chin J Exp Tradit Med Form，2024，30（12）：31-38.
  97. 97.
    OU H P，WU Q H，YUAN D，et al.Effect of Taohong Siwu decoction on apoptosis and EMT of pulmonary fibrosis model rats through JAK2/STAT3 signaling pathway［J］.Chin Pharmacol Bull，2019，39（8）：1577-1583.
  98. 98.
    SUN C B，YING Y，HOU J，et al.Study of Panax notoginseng saponins activate autophagy to alleviate pulmonary fibrosis in mice via PI3K/Akt/mTOR signaling pathway［J］.Lishizhen Med Mater Med Res，2020，31（12）：2872-2876.
  99. 99.
    LIU H，YU H，CAO Z，et al.Kaempferol modulates autophagy and alleviates silica-induced pulmonary fibrosis［J］.DNA Cell Biol，2019，38（12）：1418-1426.
  100. 100.
    LIU M W，SU M X，TANG D Y，et al.Ligustrazin increases lung cell autophagy and ameliorates paraquat-induced pulmonary fibrosis by inhibiting PI3K/Akt/mTOR and hedgehog signalling via increasing miR-193a expression［J］.BMC Pulm Med，2019，19（1）：35.
  101. 101.
    XUE L，MAO C Y，WANG H，et al.Effects of quercetin on pulmonary fibrosis in rats and its related mechanism［J］.Chin J Comp Med，2022，32（7）：94-100，117.
  102. 102.
    SHANG L L，ZHANG J，HUANG B，et al.Mechanism of saikosaponin d on autophagy of alveolar epithelial cells in idiopathic pulmonary fibrosis［J］.Chin J Integr Tradit Chin West Med，2022，42（8）：996-1001.
  103. 103.
    BAI H H，LI B，ZHANG S S，et al.Effects of apigenin on pulmonary fibrosis and autophagy of alveolar macrophages in rats via TLR4-TRAF6 axis［J］.Pharmacol Clin Chin Mater Med，2022，38（6）：90-95.
  104. 104.
    PAN Y，WANG Z X，GUO J，et al.Regulatory mechanism of Buyang Huanwu decoction on mTOR protein that mediates autophagy in mice with pulmonary fibrosis［J］.Chin J Exp Tradit Med Form，2019，25（6）：23-31.
  105. 105.
    LI P，NIU L，ZHAO G J，et al.Inhibition effect of Bufei Huoxue capsule on Bleomycin induced pulmonary fibrosis in mice based on autophagy［J］.Chin Tradit Pat Med，2019，46（4）：1337-1342.
  106. 106.
    FAN Z K，NIU X Y，WANG L D，et al.Effect of Peitu Yifei granules on autophagy mechanism in rats with idiopathic pulmonary fibrosis based on PI3K/Akt/mTOR signaling pathway［J］.China J Chin Mater Med，2024，49（14）：3878-3886.

続きを読む

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website